Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence?
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background Major Depressive Disorder (MDD) is highly prevalent, severely debilitating, and often recurrent. Greater residual depressive symptoms after acute phase treatment predict greater relapse and recurrence. It is unknown, however, which specific depressive symptoms remain and are most predictive. Method The current study examined (a) which specific residual symptoms remained after effective treatment with acute phase cognitive therapy (CT) for recurrent depression and (b) if any of those specific residual symptoms were risk factors for relapse and recurrence over 2-year follow-up. Results After completing 20 sessions of acute phase cognitive therapy of depression (CT), a substantial proportion of adult responders continued to endorse somatic anxiety (42%), psychological anxiety (37%), middle insomnia (36%), depressed mood (29%), loss of libido (29%), late insomnia (24%), anergia (21%), guilt feelings (18%), early insomnia (17%), and anhedonia (14%), as defined by the 17-item Hamilton Rating Scale for Depression (HRSD). Decreased agitation, increased psychological anxiety, increased loss of appetite, increased loss of libido, and increased hypochondriasis were all risk factors for relapse and recurrence over 2-year follow-up (all ps < .05), after stratifying on number of previous episodes and controlling for age at onset and whether acute phase CT responders received continuation phase CT instead of assessment only control. Limitations These findings are based on a limited sample size (n = 84), which was modestly restricted in terms of gender, ethnicity, region, and mean education level. Conclusions These results confirm that residual symptoms are common after acute phase CT. We hypothesize that treatments, intervention modules, or durations that effect and/or target specific residual symptoms may further reduce depression relapse and recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 15×
“• Recurrence: meeting DSM-IV criteria for MDD after the criteria for recovery were met (defined by BEV).”
MethodInfluentialKeller, M. B. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180050009 · Cited by 1,643
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791 · cited 2×
“Paykel et al. (1995) did report prevalence rates of residual symptoms following treatment with antidepressant medication in inpatients and outpatients, and found that when patients remitted from MDD, they continued to report all depression symptoms except loss of insight.”
BackgroundHooley, J. M., & Teasdale, J. D. (1989) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.98.3.229 · Cited by 740
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 2×
“Using this definition, the prevalence rates of residual symptoms range from 30%-54% whether patients receive pharmacotherapy or psychotherapy (Nierenberg et al., 1999; Paykel et al., 1995; Tranter et al., 2002).”
BackgroundInfluentialJudd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458
How does cognitive therapy prevent relapse in residual depression? Evidence from a controlled trial.
Teasdale, J. D., Scott, J., Moore, R. G., Hayhurst, H., Pope, M., & Paykel, E. S. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.69.3.347 · Cited by 269
Cognitive behavioral treatment of residual symptoms in primary major depressive disorder
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.9.1295 · Cited by 266 · cited 1×
“Some of studies have examined treating post-medication residual symptoms with CT (Fava et al., 1994; Paykel et al., 1999), with positive results.”
Background(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.8.1046 · Cited by 252
Cited by
Atlantis, E., & Sullivan, T. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02709.x · Cited by 472
“…5 Note: Weights are from random effects analysis Overall (I-squared = 62.8%, P = 0.045) Shiri et al. 2007 Taylor et al. 2010 Dryman et al. 1991W ID Dryman et al. 1991M Study 3.12 (1.66, 5.85) 1.90 (1.10, 3.30) 2.05 (1.15, 3.65) 8.90 (2.70, 29.80) ratio…”
InfluentialKaryotaki, E., Ebert, D. D., Donkin, L., Riper, H., Twisk, J., Burger, S., Rozental, A., Lange, A., Williams, A. D., Zarski, A. C., et al. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.007 · Cited by 303
Yang, X.-H., Huang, J., Zhu, C.-Y., Wang, Y.-F., Cheung, E. F. C., Chan, R. C. K., & Xie, G.-R. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.08.056 · Cited by 288
Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d6c25 · Cited by 276
Staging of Mental Disorders: Systematic Review
Cosci, F., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000342243 · Cited by 235
McClintock, S. M., Husain, M. M., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Trivedi, M. H., Cook, I., Morris, D., Warden, D., & Rush, A. J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820ebd2c · Cited by 234
Relapse and recurrence prevention in depression: Current research and future prospects
Beshai, S., Dobson, K. S., Bockting, C. L. H., & Quigley, L. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.09.003 · Cited by 165
Cognitive Behavioral Therapy for Insomnia in Depression
Asarnow, L. D., & Manber, R. (2019) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2019.01.009 · Cited by 115
Technological adjuncts to enhance current psychotherapy practices: a review
Clough, B. A., & Casey, L. M. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.12.008 · Cited by 103
Ebert, D., Tarnowski, T., Gollwitzer, M., Sieland, B., & Berking, M. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345967 · Cited by 93
Does insomnia treatment prevent depression?
Boland, E. M., Goldschmied, J. R., & Gehrman, P. R. (2023) · SLEEP · doi:10.1093/sleep/zsad104 · Cited by 69
Loeffler, L. A. K., Radke, S., Habel, U., Ciric, R., Satterthwaite, T. D., Schneider, F., & Derntl, B. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.10.025 · Cited by 47
Boland, E. M., Vittengl, J. R., Clark, L. A., Thase, M. E., & Jarrett, R. B. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.10.033 · Cited by 29
Self-citationNunes, A., Pavlova, B., Cunningham, J. E. A., Nuñez, J.-J., Quilty, L. C., Foster, J. A., Harkness, K. L., Ho, K., Lam, R. W., Li, Q. S., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.023 · Cited by 5
Metadata
- Authors
- Taylor, D. J., Walters, H. M., Vittengl, J. R., Krebaum, S., & Jarrett, R. B.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 123
- Issue
- 1-3
- Pages
- 181-187
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2070647033
- Cited by
- 109
- References
- 16
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.